Adamis Pharmaceuticals Corp
ADMP
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.25M
Close$
Share Statistics
| Market cap | $7.25 Million |
|---|---|
| Enterprise Value | $-6,420,679,674.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.24 |
| Beta | 1.28 |
| Outstanding Shares | 7,065,673 |
Return
| Return on Equity | 0.23% |
|---|---|
| Return on Assets | -0.13% |
| Return on Invested Capital | 0.41% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.78 |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -510.47 |
| Enterprise Value to EBIT | 350.18 |
| Enterprise Value to Net Income | 559 |
| Total Debt to Enterprise | -0.04 |
| Debt to Equity | -0.05 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About DMK Pharmaceuticals Corporation
11 employees
CEO: Eddie Wabern Glover DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical...